The approval establishes the first and only FDA-approved ophthalmic formulation of bevacizumab for neovascular age-related macular degeneration in the US.
Drawing on his experience caring for veterans in northern California, Frank Brodie, MD, MBA, explains why gene therapy may be particularly meaningful for patients who travel long distances for routine anti-VEGF treatment.
At the Focus A-Eye Summit, in the session “Lessons from Formula One: Optimizing Clinical Workflow with AI,” experts examined how artificial intelligence can streamline and accelerate ophthalmic clinical workflows.
Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.